NICE considers Rivaroxaban cost-effectve for DVT

By Professor Juan Tamargo, Madrid, Spain

The UK National Institute for Health and Clinical Excellence (NICE) concluded that the oral factor Xa inhibitor rivaroxaban is a cost-effective alternative to warfarin for treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism.

NICE says rivaroxaban can be used as an option for treating DVT and for preventing recurrent DVT and pulmonary embolism in adults diagnosed with DVT.